drugset
drugset / Trial / NCT05446233

ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects

NCT05446233 ↗

Phase 1 Completed 6 enrolled Sunshine Lake Pharma Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] Antaitavir Hasophate.

Timeline

Start
2022-11-15
Primary completion
2023-01-02
Completion
2023-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Antaitavir Hasophate Unknown 100 mg Oral

Indications

No indication recorded.